
Moderna ESG Day

November 10th, 2022






© 2022 Moderna, Inc. All rights reserved.

Forward-looking statements and disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the impact of a fall COVID-19 booster campaign on lives and dollars saved; the potential of Moderna's mRNA platform to address significant unmet medical needs; the potential for Moderna's late stage pipeline to have meaningful impact across several therapeutics areas; Moderna's global health strategy, including pandemic preparedness and Moderna's commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025; Moderna's commitment to vaccines and therapeutics access; Moderna's environmental sustainability strategy, including its commitment to achieve net-zero carbon emissions in its global operations (Scopes 1 & 2) by 2030; Moderna's commitment regarding Scope 3 emissions; Moderna's intention to report to CDP and align with TCFD recommendations; diversity in Moderna's clinical trials and Moderna's ability to meet demographic objectives; the build out of Moderna's regional manufacturing capability, including building infrastructure in Africa; and the impact of the Moderna Charitable Foundation. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the guarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation.

Moderna's mission and five focus areas of our corporate responsibility framework

To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.





Today is Moderna's first ESG Day

Launched **corporate social responsibility framework** in 2018

Released first Environmental, Social and Governance (ESG) report in June 2022


Today's goal is to **engage** stakeholders, highlight progress and be transparent on our ESG journey



https://assets.modernatx.com/m/ccaae809ca9152c/original/M oderna_ESG_2021.pdf



Medicines for patients



Moderna has a diverse portfolio of vaccine and therapeutic programs in preclinical and clinical development

			Preclinical	Phase 1	Phase 2	Phase 3	Licensed
	mRNA-1273	SARS-CoV-2					
	mRNA-1345	RSV (older adults)					
	mRNA-1010	Seasonal Flu (HA)					
	mRNA-1283	SARS-CoV-2					
	mRNA-1073	COVID + Flu					
Respiratory Infectious	mRNA-1020/-1030	Seasonal Flu (HA+NA)					
Diseases	mRNA-1345	RSV (pediatrics)					
Biscusco	mRNA-1653	hMPV + PIV3 (pediatrics)					
	mRNA-1011/-1012	Seasonal Flu (HA)					
	mRNA-1230	COVID + Flu + RSV					
	mRNA-1287	HCoV					
	mRNA-1365	RSV + hMPV (pediatrics)					
	mRNA-1647	CMV					
	mRNA-1893	Zika					
Latent and Global	mRNA-1189	EBV					
	mRNA-1574, 1644	HIV					
Health Infectious	mRNA-1215	Nipah					
Diseases	mRNA-1195	EBV Therapeutic					
	mRNA-1468	VZV					
	mRNA-1608	HS∨					
	mRNA-3927	PA					
	mRNA-3705	MMA					
	mRNA-3745	GSD1a					
Rare Diseases	mRNA-3692	CFTR (Vertex)					
	mRNA-3351	CN1					
	mRNA-3602	PKU					
	mRNA-3139	OTC					
	mRNA-4157	PCV (Merck)					
	mRNA-5671	KRAS					
Oncology	mRNA-2905	IL-12					
0,	mRNA-2752	Triplet					
	mRNA-4359	Checkpoint Vaccine					
Autoimmune	mRNA-6981	PD-L1					
Cardiovascular	AZD8601	VEGF-A					
	mRNA-0184	Relaxin					



Moderna's mRNA technology has enabled the rapid development of our infectious disease vaccines portfolio

			Preclinical	Phase 1	Phase 2	Phase 3	Licensed
m	nRNA-1273	SARS-CoV-2					
	nRNA-1345	RSV (older adults)					
m	nRNA-1010	Seasonal Flu (HA)					
m	nRNA-1283	SARS-CoV-2					
	nRNA-1073	COVID + Flu					
Respiratory Infectious m	nRNA-1020/-1030	Seasonal Flu (HA+NA)					
Diseases n	nRNA-1345	RSV (pediatrics)					
m	nRNA-1653	hMPV + PIV3 (pediatrics)					
m	nRNA-1011/-1012	Seasonal Flu (HA)					
n an	nRNA-1230	COVID + Flu + RSV					
n 🔤	nRNA-1287	HCoV					
r	nRNA-1365	RSV + hMPV (pediatrics)					
r	nRNA-1647	CMV					
n n	nRNA-1893	Zika					
Latent and Public	nRNA-1189	EBV					
Health Infectious ^m	nRNA-1574, 1644	HIV					
– •	nRNA-1215	Nipah					
	nRNA-1195	EBV Therapeutic					
	nRNA-1468	VZV					
	nRNA-1608	HSV					
	nRNA-3927	PA					
	nRNA-3705	MMA					
	nRNA-3745	GSD1a					
	nRNA-3692	CFTR (Vertex)					
	nRNA-3351	CN1					
	nRNA-3602	PKU					
	nRNA-3139	OTC					
	nRNA-4157	PCV (Merck)					
	nRNA-5671	KRAS					
	nRNA-2905	IL-12					
	nRNA-2752	Triplet					
r	nRNA-4359	Checkpoint Vaccine					
Autoimmune m	nRNA-6981	PD-L1					
A small as a set of the set of th	ZD8601	VEGF-A					
	nRNA-0184	Relaxin					



The impact of safe and effective vaccines on global health, economies and social welfare is undeniable



We have had the privilege of protecting **hundreds of millions of people** in 2021 & 2022 with our COVID vaccines



Resulting in an estimated **1.7 million deaths averted** in 2021 because of Moderna's vaccine alone¹



A fall COVID-19 booster campaign could save thousands of lives and billions of dollars²



We hope to have a large impact on human health with many more of our vaccines

Moderna's mRNA platform enables us to rapidly develop many vaccines, potentially allowing us to address significant unmet medical needs

In our prophylactic vaccine modality, we have:

33 development programs

26 in the clinic

4 in Phase 3



Our mRNA vaccine technology advantages facilitates development of:


- vaccines to address unmet needs (no vaccines available)
- vaccines against latent viruses
- **S** combination vaccines



Climate change is aggravating human pathogenic diseases

A pathogen and a person coming into contact is the most important factor for the emergence of a human pathogenic disease

Subset of diseases aggravated by climatic hazards compared with all reported infectious diseases



Climate change is leading to a **shift in the geographical range of species** (increasing range expansion of vectors with warmer weather, disrupting habitats)

Climatic hazards facilitated the contact between people and pathogens by **moving people closer to pathogens**

Climate change has also **enhanced specific aspects of pathogens**



Utilizing our mRNA vaccine technology to accelerate pandemic preparedness globally

Priority Pathogens

Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025

mRNA Access™

New collaborative access enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases

Regional Manufacturing

Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak



Our mRNA therapeutics pipeline addresses unmet medical needs and has the potential to transform the lives of many patients

			Preclinical	Phase 1	Phase 2	Phase 3	Licensed
	mRNA-1273	SARS-CoV-2					
	mRNA-1345	RSV (older adults)					
	mRNA-1010	Seasonal Flu (HA)					
	mRNA-1283	SARS-CoV-2					
	mRNA-1073	COVID + Flu					
espiratory Infectious	mRNA-1020/-1030	Seasonal Flu (HA+NA)					
Diseases	mRNA-1345	RSV (pediatrics)					
2100 4000	mRNA-1653	hMPV + PIV3 (pediatrics)					
	mRNA-1011/-1012	Seasonal Flu (HA)			-		
	mRNA-1230	COVID + Flu + RSV					
	mRNA-1287	HCoV					
	mRNA-1365	RSV + hMPV (pediatrics)					
	mRNA-1647	CMV					
	mRNA-1893	Zika					
Latent and Public	mRNA-1189	EBV					
	mRNA-1574, 1644	HIV					
Health Infectious	mRNA-1215	Nipah					
Diseases	mRNA-1195	EBV Therapeutic					
	mRNA-1468	VZV					
	mRNA-1608	HSV					
	mRNA-3927	PA					
	mRNA-3705	ММА					
	mRNA-3745	GSD1a					
Rare Diseases	mRNA-3692	CFTR (Vertex)					
	mRNA-3351	CN1					
	mRNA-3602	PKU					
	nRNA-3139	OTC					
	nRNA-4157	PCV (Merck)					
	nRNA-5671	KRAS					
Oncology	nRNA-2905	IL-12					
	nRNA-2752	Triplet					
	mRNA-4359	Checkpoint Vaccine					
Autoimmune	mRNA-6981	PD-L1					
Cardiovascular	AZD8601	VEGF-A					
Culdiovasculdr	mRNA-0184	Relaxin					



Moderna-Institute For Life Changing Medicines (ILCM) collaboration

- Crigler-Najjar syndrome is a severe condition that can lead to jaundice and damage to the brain, muscles and nerves. The symptoms become apparent shortly after birth and can be life-threatening
 - It is estimated that there are only approximately 70-100 known cases of CN-1 in the world
- The goal of the collaboration is to make an mRNA therapy for the **treatment of CN-1 available at no cost to patients**
- Under the terms of the agreement, Moderna will license mRNA-3351 to ILCM with no upfront fees, and without any downstream payments
- ILCM will be responsible for the clinical development of mRNA-3351



https://www.lifechangingmedicines.org/




mode


We are committed to reach as many people as possible

Moderna's Commitment to Vaccines and Therapeutics Access

December 23, 2020



Employees



15 © 2022 Moderna, Inc. All rights reserved.

Moderna seeks to attract and retain the best talent

- Patients/people and the impact first
- Diversity & inclusion efforts
- Employee resource groups
- Ensuring employees have **financial** and mental well-being



moderna

Science 2022


OP EMPLOYERS







Environment



Climate change is increasingly affecting the foundations of human health




Moderna is committed to achieve **net-zero** carbon emissions in our global operations (Scopes 1 & 2) by 2030

For Scope 3, Moderna is committed to defining a near-term science-based target and evaluating a long-term target





Community



Committed to having a positive impact on communities around the world










Corporate Volunteering Employee Gift Matching Philanthropic Giving Humanitarian Relief









Building Moderna in the right way



ESG accountability at Board and Executive Committee level



Starting our journey by increasing transparency across our supply chain




Increased disclosure of ESG data and our progress



Today's agenda

Moderna's Mission and Culture to Drive Impact	Stéphane Bancel, Chief Executive Officer	
Medicines for Patients		
Overview of mRNA Vaccines and Therapeutics	Stephen Hoge, President	
Inclusive Research at Moderna	Jameka Hill, Director, Patient Engagement and Trial Diversity	
Global Health Strategy	Hamilton Bennett, Senior Director, Vaccine Access & Partnerships	
Culture & Employees	Tracey Franklin, Chief Human Resources Officer	
Communities	Katherine O'Malley, Executive Director, Internal Communications and Employee Engagement	
Coffee Break (5 minutes)		
Environment	Deborah Donovan, Senior Vice President, Environmental, Health & Safety, Technical Development and Manufacturing	
Governance and Ethics	Shannon Thyme Klinger, Chief Legal Officer, President Moderna Charitable Foundation	
Conclusion	Stéphane Bancel, Chief Executive Officer	
Q&A		






Overview of mRNA Vaccines and Therapeutics

Stephen Hoge, M.D.


President



mRNA is a new class of medicine










Moderna's late stage pipeline has the potential to have meaningful impact across several therapeutic areas

Respiratory infections are **a top cause of death** globally (3 million deaths) Approximately **4% of the total world population** is affected by a rare disease at any given time

Cancer impacts large portions of the population



There are about 7,000 known rare diseases

Leads to 10 million deaths annually across the world

https://www.ajmc.com/view/not-so-rare-300-millionpeople-worldwide-affected-by-rare-diseases

ational Center r Advancing anslational Sciences

https://www.who.int/news-room/fact-sheets/detail/cancer



Today you will hear about two key aspects of our R&D organization




Diversity and inclusion in clinical trials

- Investing to be the leader in diversity & inclusion in clinical trials
- Focus on all stages of clinical development (Phase 1 to Phase 3), not just the large, pivotal trials



- Aiming to enhance capabilities and infrastructure to improve global health outcomes, including pandemic preparedness
- Partnering with institutions across the world on R&D for priority pathogens





Inclusive Research at Moderna

Jameka Hill

Director, Patient Engagement and Trial Diversity



Why is diversity in clinical trials so important?

Drugs and vaccines are safer and more effective for everyone when clinical trials include everyone

- People of different ages, sexes, races, and ethnicities may react differently to certain medicines and vaccines
- When a clinical trial population is homogenous, research results may be skewed resulting in data that would not be generalizable to a wider patient population
- Clinical trials historically have been underrepresented in sex/age/race/ethnicity in the U.S.


Racial and ethnic minorities currently make up ~40% of the U.S. population

But racial and ethnic minorities have historically been severely underrepresented in clinical trials

US Census Bureau, <u>https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html#:~:text=The%202020%20Census%20shows%20(Figures.in%20combination%20with%20another%20group</u>

How does Moderna define diversity in clinical research?

- Diversity exists across many dimensions
- Diversity is context-specific
- The importance of each factor may vary depending upon the disease/condition and the population at risk





Women and minorities have historically been underrepresented in clinical trials

Year	Regulatory Efforts to Address Underrepresentation
1993	The National Institutes of Health (NIH) adopted a policy in 1993 mandating all federal grants for clinical research include women and minorities.
2014	The FDA launched a website called <i>Drug Trials Snapshots</i> to provide the public with information about the demographic composition of the data collected in clinical trials of newly- approved medications.
2020	The FDA issued guidance for the industry to improve diversity and representation in clinical trials.
2022	The FDA expanded on previous guidance (2020) for the industry to improve diversity and representation in clinical trials. This new guidance recommends submitting a "Race and Ethnic Diversity Plan" for all new drug and medical device submissions from the early clinical trial phases.



FDA

Source: FDA



Reluctance to participate in clinical trials

Mistrust	Limited Awareness of Tr	rials Lack of Invitation to Participate			
Lack of Informo	ation Logistical	Obstacles – Time & Resource Constraints			
Complexity	of Protocol – Study Burden	Ethnic & Cultural Beliefs			
Language/Lite	Language/Literacy Eligibility Criteria/Comorbid Conditions				




What constitutes diversity in Moderna clinical trials

Race, ethnicity, age, and sex can all **impact how different people respond to the same medicine or vaccine**

At Moderna, a clinical trial can be qualified as "diverse" in healthy volunteer trials when:


- 37% of the sample population within the US are Persons Of Color
- 50% female assigned at birth
- Balance across age cohorts



https://www.brookings.edu/blog/the-avenue/2018/03/14/the-us-will-become-minority-white-in-2045-census-projects/ https://unstats.un.org/unsd/demographic-social/products/worldswomen/documents/Population_BW.pdf https://www.un.org/development/desa/en/news/population/our-world-is-growing-older.html



Diversity in clinical trials: where we were in 2020



Subpopulation for New Molecular Entities and Therapeutic Biologics Approved (2020)

moderna

Moderna's approach to reach underrepresented groups

Drive strategy and manage initiatives to build trust and ensure medically underrepresented groups can be better engaged in our clinical trials

- Embed the importance of diversity in clinical trials into our company's culture
- Establish demographic objectives and diversity plans for each trial (Phase 1-3)
- Select multi-regional clinical trial sites with inclusion in mind
- Increase ways to access trials
- Collaborate with trusted voices
- Develop outreach and education tailored to specific populations
- Leverage dashboard and metrics to understand historical performance within specific indications, inform site selection and enrollment strategy, and measure future performance







Ensured that we enrolled diverse and at-risk populations for our Phase 3 COVID-19 vaccine trial (COVE Study)

Slowed enrollment in the COVE study to ensure diverse representation


Included more than 11,000 participants from communities of color, representing 37% of the study population





COVE study: Racial ethnic demographics







38

Leveraging our digital infrastructure to support trial diversity

Real-time D&I comparison to census

• Empowered COVE clinical team decision making and made an impact for populations most at risk

Shared insights across multiple teams

 Shared insights from central location with Moderna teams, clinical research organizations (CROs), government partners, company website & more Evolution of diversity throughout enrollment

Interim data snapshot - October 21, 2020 - subject to change

White Participants
 Participants Of Color

moderna

Our pivotal Phase 3 trials in RSV and CMV are both on track to meet demographic objectives





US Enrollment Targets Based on Demographic Composition

US Enrollment Targets Based on
Demographic Composition

	Objective	Current %		Objective	Current %
White	69%	65%	White	58%	52%
Persons of color	31%	35%	Persons of color	42%	48%

Data as of September 8, 2022



Striving to be a leader in the industry


Moderna continues to lead the industry, proving that concerted efforts to provide equitable healthcare access to all populations are both possible and essential.



56%

56%

U.S. Participants of Color Across 13 Vaccine Trials (Phase 1-3) % (n)



2020 - 2022

Summary



Clinical trial diversity is not solely our ethical responsibility – it is also a scientific imperative




Moderna **leverages our digital infrastructure** to enable meaningful action through real time data transparency



Improving trial diversity is a vital step towards **achieving health equity and helping improve lives around the world**






Moderna's Global Health Strategy

Hamilton Bennett

Senior Director, Vaccine Access & Partnerships



We have been committed to using our mRNA platform for global health since our founding



Key pillars of our global health strategy

Priority Pathogens

Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025

mRNA Access™

New collaborative program enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases

Regional Manufacturing

Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak



Priority pathogens

Priority Pathogens

Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025

mRNA Access™

New collaborative access enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases

Regional Manufacturing

Ē

Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak



Pandemic and epidemic threats will continue to arise

PNAS

"Using recent estimates of the rate of increase in disease emergence from zoonotic reservoirs associated with environmental change, we estimate that the yearly probability of occurrence of extreme epidemics can increase up to threefold in the coming decades."

Marani, Marco et al., PNAS (2021), https://doi.org/10.1073/pnas.2105482118

THE LANCET Infectious Diseases

"Disease X is caused by Pathogen X, an infectious agent that is not currently known to cause human disease, but an aetiologic agent of a future outbreak with epidemic or pandemic potential...although viral pathogens represent a small proportion of the pathogens that account for emerging infectious disease events, the most devastating recent emergence events have involved RNA viruses."

moderno

Our platform is uniquely suited to address persistent and emerging threats

Persistent Global Health Threats (WHO, CEPI and others)	Prototype Viral Family
Chikungunya virus	Togaviridae
COVID-19	Coronaviridae
Crimean-Congo haemorrhagic fever	Nairoviridae
Dengue	Flaviviridae
Ebola virus disease	Filoviridae
HIV	
Malaria	
Marburg virus disease	Filoviridae
Lassa fever	Arenaviridae
Middle East respiratory syndrome coronavirus (MERS-CoV)	Coronaviridae
Nipah and henipaviral diseases	Paramyxoviridae
Rift Valley fever	Phenuiviridae
Severe fever with thrombocytopenia syndrome	Phenuiviridae
Tuberculosis	
Zika	Flaviviridae
"Disease X"	

Committed to advancing into clinical studies a portfolio of at least 15 vaccine programs targeting emerging or neglected infectious diseases by 2025

Focused on advancing vaccines that address current diseases of significant impact to low- and middle-income countries, and those that prepare for "Disease X"

WHO: <u>https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts;</u> CEPI: <u>https://100days.cepi.net/vaccine-libraries/</u>

Meaningful progress has been made against prioritized global health programs

Priority Pathogen	ID #	Preclinical Dev	Phase 1	Phase 2	Phase 3	Commercial	Collaborators
COVID-19	mRNA-1273						BARDA/NIAID
Zika	mRNA-1893						BARDA
Chikungunya	mRNA-1388						
HIV	mRNA-1644						IAVI / Others
HIV	mRNA-1574						IAVI/BMGF/NIAID & Others
Nipah	mRNA-1215						NIH
Monkeypox	mRNA-1769						
Ebola							UTMB
Dengue							
Lassa							UTMB
MERS-CoV							
Marburg							UTMB
Malaria							
CCHF							
Rift Valley Fever							
SFTS							KNIH
Tuberculosis							

Source: Compiled from Global Health groups.

Abbreviations: CCHF, Crimean Congo Hemorrhage Fever; HIV, human immunodeficiency viruses; M ERS-CoV, Middle East respiratory syndrome coronavirus; SFTS, Severe fever with thrombocytopenia syndrome.

HIV is an example of leveraging collaborations to advance programs against an unmet need



Human immunodeficiency virus (HIV)	 Belongs to a class of viruses known as retroviruses Primary routes of transmission are sexual intercourse and IV drug use, putting young adults at highest risk of infection 		
Circulation	 Approximately 1.5 million <u>new infections</u> are acquired worldwide each year, and 650,000 people die 		
Disease burden	Responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure		
Moderna vaccine clinical stage	mRNA-1644 (B cells) Phase 1 ongoing in U.S. mRNA-1574 (HIV trimers) Phase 1 ongoing in U.S.		
Collaborators	National Institute of Allergy and Infectious Diseases BILL & MELINDA GATES foundation		



mRNA Access

Priority Pathogens

Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025

mRNA Access™

New collaborative access enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases

Regional Manufacturing

Ē

Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak



Mission of mRNA Access



powered by moderna®



Create life saving medicines: To accelerate innovation and enable new medicines for emerging and neglected infectious disease through decentralized research and development (R&D)

Additional benefits



Engage Disease-Area Experts: To

engage a community of researchers to tackle the global health priorities of our generation



Inspire Future Scientists: To educate a new generation of scientists and engineers on the use of mRNA as a technology and fuel future innovation



mRNA Access Powered by Moderna



mRNA Design Studio

Our custom mRNA is codon optimized for optimal expression and manufacturability



High-Throughput Production

Optimized mRNA is manufactured using our prophylactic vaccine process, suitable for *in vitro* or *in* vivo testing

Iterative Research

The speed and flexibility of our platform allows for rapid designtest cycles of antigen design and pre-clinical testing



mRNA Access is targeting emerging and neglected infectious diseases

• Existing & Planned Programs

- Alkhurma virus
- Andes virus
- Bacillus anthracis (anthrax)
- Balamuthia mandrillaris
- Barmah Forest virus (BFV)
- Brucella species (brucellosis)
- Burkholderia mallei (glanders)
- Burkholderia
 pseudomallei (melioidosis)
- Cache Valley virus
- Caliciviruses
- California encephalitis virus
- Campylobacter jejuni
- Canine distemper (morbilli)
- Cedar (henipa)
- Chapare virus
- Chikungunya virus
- Chlamydia psittaci (psittacosis)
- Clostridium botulinum toxin (botulism)
- Coccidioides spp.
- Coxiella burnetii (Q fever)
- Crimean-Congo haemorrhagic fever (CCHF)

Source: Compiled from Global Health groups.

© 2022 Moderna, Inc. All rights reserved.

- Cryptosporidium parvum
- Cyclospora cayatanensis
- Deer tick virus

54

- **Dengue** (flaviviridae proto)
- Eastern equine encephalitis (EEE)
- Ebola: Sudan and Zaire virus
- Echovirus

Potential Future Programs

- Entamoeba histolytica
- Enterovirus A71
- Enterovirus D68
- Francisella tularensis (tularemia)
- Giardia lamblia
- Guanarito virus
- Hantaan virus
 - Hantaviruses causing hanta pulmonary syndrome
 - Hazara virus
 - Hendra virus
 - Hepatitis A
 - Hepatitis C
 - Hepatitis E
 - Hookworm (N. americanus)
 - HPIV (1 or 3)
 - Human Immunodeficiency Virus (HIV)
 - Human T-cell leukaemia virus (HTLV-1)
 - Influenza virus A pandemic
 - Japanese encephalitis virus (JE)
 - Junin virus

- Kyasanur Forest virus
- Kumasi virus
- LaCrosse encephalitis (LACV)
- Lassa fever
- Leishmaniasis
- Leptospirosis
- Listeria monocytogenes (Maternal)
- Lujo virus
- Machupo virus
- Malaria
- Marburg and Ravn virus
- Menagle virus
- Meningocococcal meningitis
- MERS-CoV
- Microsporidia
- Mojiang virus
- Monkeypox/Smallpox
- Naegleria fowleri
- Nipah virus
- Omsk hemorrhagic fever virus
- O'nyong-nyong virus
- Phlebovirus (bunyavirales)
- Powassan virus
- Punta Toro
- Rabies virus
- Rhinovirus C
- Ricin toxin (ricinus communis)

- Rickettsia (spotted fevers)
- Rift Valley fever
- Salmonella (typhoid/paratyphoid fever)
- SARS-CoV-1
- SARS-CoV-2
- Schistosomiasis (S. Mansoni)
- Semliki Forest virus (SFV)
- SFTS virus
- Shigella species
- Sin Nombre virus
- Sosuga virus
- St. Louis encephalitis virus (SLEV)
- Staphylococcus enterotoxin B (SEB)
- Toxoplasma gondii
- **Tuberculosis**, including drugresistant TB
- Venezuelan equine encephalitis
 (VEE)
- Vibrio (pathogenic)
- West Nile virus (WNV) (flaviviridae proto)
- Western equine encephalitis (WEE)
- Yellow fever virus (YFV)
- Yersinia pestis (plague)
- Zika virus



mRNA Access Collaborators





















Regional manufacturing

Priority Pathogens

Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025

mRNA Access™

New collaborative access enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases

Regional Manufacturing

Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak



We are building <u>regional</u> manufacturing capability to prepare for the future

Facilities around the world can be important pillars of response to any pandemic outbreak



Making progress in building infrastructure in Africa



Update on Kenya manufacturing facility

- Moderna announced in March 2022 that it had selected Kenya for its first manufacturing site in Africa
- Site selection close to being finalized, subject to reaching an agreement with the government of Kenya
- While discussions were paused during Kenyan elections, **discussions** ongoing with President Ruto's administration
- Strong support from the US government, including the US Ambassador to Kenya, Meg Whitman



Summary



Moderna has been committed to global health since its founding in 2010, leveraging the power of mRNA



Committed to bringing forward at least 15 pathogens into the clinic in order to help prepare for any future pandemics




Sharing our mRNA platform with collaborators worldwide through mRNA Access is an important part of continued efforts to address emerging and neglected infectious diseases



Building regional manufacturing facilities in order to be able to respond to regional outbreaks worldwide






Moderna Culture & Employees

Tracey Franklin

Chief Human Resources Officer



Moderna has expanded rapidly in the last few years



Headcount expansion:

Since our IPO in 2018, we have increased our employee headcount ~5X

* headcount as of October 2022




Geographic expansion:

We now have employees in 15 global jurisdictions, with more to come in 2023



We have made progress in representation



- 1. Global
- 2. US only
- 3. Gender globally and race/ethnicity in U.S.
- 4. Defined as employees at Vice President level and above



62 © 2022 Moderna, Inc. All rights reserved.

Ever since Moderna was founded, we have consistently strived to recruit the best talent from around the world

N

~185

Employees with a Green Card sponsored by Moderna

34

Nationalities currently represented

>90%

of our Executive Committee have lived and/or worked outside the US

>300

Employees working with active visa status





Our philosophy toward diversity and inclusion starts with belonging, the most challenging but essential focus area

Lead with **Drive a Culture** Grow of Inclusion **Belonging Diversity** moderna moderna



Video: Moderna employees

moderna

The People Behind the Science

https://www.modernatx.com/careers/people-behind-the-science



We have a concrete strategy to continue to advance our Belonging, Inclusion, and Diversity efforts

Roadmap We have developed a holistic five-year Belonging, Inclusion & Diversity roadmap

- Internal Moderna's nine employee resource groups are focused both on affinity and enhancing the company culture
- **External** We benchmark our performance versus verified third-party benchmarks



Signatory company since 2020



Moderna © @moderna_tx - Jan 28 Our CEO, Stéphane Bancel, is proud to be one of the 100 CEOs who've signed the CEO Latter on Disability Inclusion as part of @DisabilityIN's global #CEOsAveIN campaign. Together, we can all work to create infocuative workplaces.

Disability:IN @ @DisabilityIN · Jan 27
 #CEOArelNI Through the CEO Letter on Disability Inclusion, 100
 leaders are urging peers to participate in the Disability Equality Index
 (MDEI). Learn more at ow.//KRYKSDHPyzT





95/100 Score from 2022 Human Rights Campaign Corporate Equality Index, our first rating



We adopt advanced listening tools to identify areas of focus to create an environment where our unique workforce can have the most impact

Learning Moderna University Leadership, Culture CMC Research & External Digital & Management Development Sciences Engagement Colleges Educating our workforce on Learning as a lever for Transforming leaders to build Building knowledge base fo the science underlying our Growing our ability to digitize innovation, greater impact the skills and futures required the relentless pursuit of medicines, enabling us to everywhere to push the limits in markets with stakeholder for bold leadership optimization in an everof science. and better outcomes for prioritize the platform and throughout Moderna chanaina world. push past possible. patients Moderna Science and Technology Digital Foundations Executive Development Moderna Supply Chain $\mathbf{\Xi}$ Strategic Marketing 1 Trends and Innovation in Yuman Health Stakeholder Engagement $\mathbf{\Xi}$ 2 Cyber Security 2 Moderna Manaae Safely & Security Academies perational Effectivenes Culture 2 Clinical Research 3 Artificial Intelligence 3 Policy & Access Quality Assurance Public Health Polic & Regulatory Science Pipeline Advanced Manufacturina Digital Business Proces 0 Data & Analytics Moderna Technicians Digital Ambassadors 0 Medical Affairs Digital Professionals

Well-being

BUILD THE PATH TO YOUR BEST SELF

We recognize and celebrate the fact that our wonderfully unique colleag have their own abilities, needs and interests. Moderna's benefits are designed to help you build your path to the best version of you.

While we recognize there's still more work to do, we want to thank you for joining us as we ev We are excited for our future, just as much as we are proud of our progress.

WANT TO FIND OUT MORE? For even more information visit modernabeeviffs.com Your family can also access our virtual fair using access code "Mederna"

Museuma 2023 Rummary Datas





Elevating learning at Moderna will help us write our next chapter


Our vision for learning at Moderna

Moderna becomes a 'beacon of education' and recognized globally as the pre-eminent talent development destination in biopharma and beyond.

We achieve this by providing innovative and transformational learning, upskilling, and career development opportunities to our employees and designing an ecosystem to build culture, promote well-being, and drive high-performance.



Investing in learning enables us to give back internally and externally



Introduce employees at all levels to the science at the heart of our technology.

70


 Intent to launch our external mRNA and Moderna Science certificate program

modernc

How mRNA medicine will change the

We've developed a customized set of total rewards to support the well-being of our employees

Primary domains of employee health and well-being at Moderna



spring health moderna[,] Support for Achieving Your Best Spring Health work-life services offer you and your family support for both work and personal life, including legal services, financial services, and guidance on and

Ethnicity among Specialties among Spring Health Providers Spring Health Providers 45% BIPOC 30% LGBTQ+ 24% Black 24% Racial Identity 6% Asian 23% Gender Identity 13% Latinx 8% of Spring Health Providers speak Spanish 15 unique racial groups represented 34 languages spoken fluently

moderna

Understanding Moderna's Equity Awards

Moderna provides Long-Term Incentives (LTIs) in the form of equity awards to reward you for your contributions to our success. Through Moderna's equity awards program, there are generally two award types: Non-Qualified Stock Options (Stock Options) and Restricted Stock Units (RSUs). Both Stock Options and RSUs are Long-Term Incentives, and both ultimately give you an ownership stake in Moderna through Moderna stock. As our stock rises, so can your potential wealth.

This guide will help you learn more about your equity awards. You can use the icons below to navigate throughout the guide.

on Enville Assesses Mark



www


We measure and hold ourselves accountable to how we're performing against key employee metrics

We consistently achieve above benchmark scores on engagement, culture, and belonging



Since 2021 we've included a **belonging metric in our corporate scorecard**, which impacts executive compensation





Communities

Katherine O'Malley

Executive Director, Internal Communications and Employee Engagement



Vulnerable communities have been disproportionally impacted by the COVID-19 pandemic


Unequal negative effects on the broader social determinants of health observed in 2021²



74 © 2022 Moderna, Inc. All rights reserved.

1. https://www.who.int/health-topics/social-de termi nants-of-health#tab=tab_1 2. https://www.who.int/publications/i/item/9789240038387

We strive to extend our positive impact on society





Engaging with our communities is critical to deliver on the promise of mRNA







"There's nothing more normal than neighbors working together. Moderna makes it possible for us to meet and work alongside our neighbors— building community to help communities return to normal."

Moderna employee, 2022



"Volunteering at Heading Home was a humbling experience. We are so focused on our day-today work and family lives that we sometimes lose sight of our greater purpose. Small acts of kindness can make a huge difference in other people's lives." Moderna employee, 2022 STEM Education Day at Fenway Park, October 2022

Engage the next generation of scientists

Address health literacy gap across our communities

Close the opportunity gap in underserved communities

"A key highlight was seeing my impassioned colleagues speak to the science of mRNA in a relatable way to eager students and then immediately see the curiosity and excitement on the students' faces. It was a great event to continue our community partnership and showcase our science!" Moderna employee, 2022



76 © 2022 Moderna, Inc. All rights reserved.

Launched Moderna Charitable Foundation in 2022

The Moderna Foundation reflects our commitment to giving back to help ensure a stronger and more equitable post-pandemic world through grants, humanitarian support and a new employee matching gift program.

Philanthropic giving

With a special focus on addressing the impact of COVID-19, support organizations and causes that:

Promote public health and access to quality healthcare



Advance scientific education and innovation



Advocate for inclusion and diversity

Employee Gift Matching

All employees able to participate and direct funds to their preferred organizations









Promoting public health and access to quality healthcare



• Moderna Foundation awarded a total of \$4 million to three organizations focused on improving health systems and healthcare in sub-Saharan Africa







Link to more detail



Case study: Moderna Foundation is partnering with Seed Global Health for long-lasting impact and change at system level

🕨 YouTube

https://www.youtube.com/ watch?v=ZPCr-hGkLLw



Celebrating Ten Years of Seed Global Health



79 © 2022 Moderna, Inc. All rights reserved.

Case study: Moderna Foundation is partnering with Seed Global Health for long-lasting impact and change at system level



Dedicated to support our partners in sub-Saharan Africa to create lasting change in the health system. Current partner countries include: **Malawi, Sierra Leone, Uganda**, **and Zambia**.



Training **nurses**, **midwives**, and **physicians**; building complete, fit-for-purpose **health workforce teams** that can provide high-quality care and save lives.



Forming **deep**, **locally-led partnerships** that inform our work at both the individual and systems levels.


Moderna Foundation's grant will aid in the development of the **health workforce** in **partner countries** by providing clinical education and training, focusing on national quality improvement and creating a model to scale and retain healthcare workers.



Coffee break: To resume in 5 minutes

Moderna's Mission and Culture to Drive Impact	Stéphane Bancel, Chief Executive Officer
Medicines for patients	
Overview of mRNA vaccines and therapeutics	Stephen Hoge, President
Inclusive research at Moderna	Jameka Hill, Director, Patient Engagement and Trial Diversity
Global health strategy	Hamilton Bennett, Senior Director, Vaccine Access & Partnerships
Culture & employees	Tracey Franklin, Chief Human Resources Officer
Communities	Katherine O'Malley, Executive Director, Internal Communications and Employee Engagement
Coffee break	
Environment	Deborah Donovan, Senior Vice President, Environmental, Health & Safety, Technical Development and Manufacturing
Governance and ethics	Shannon Thyme Klinger, Chief Legal Officer, President Moderna Charitable Foundation
Conclusion	Stéphane Bancel, Chief Executive Officer
Q&A	





Environment

Deborah Donovan

Senior Vice President, Environmental, Health & Safety, Technical Development & Manufacturing



Human activity has a clear and visible impact on atmospheric conditions



The India Gate war memorial in New Delhi, India, on October 17, 2019. Anushree Fadnavis/Adnan Abidi/Reuters



The India Gate war memorial in New Delhi, India, on April 8, 2020, after a 21-day nationwide lockdown. Anushree Fadnavis/Adnan Abidi/Reuters



Climate change is increasingly affecting the foundations of human health

The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels

Countdown The 2022 report of the Lancet Countdown on health and @* climate change: health at the mercy of fossil fuels while Russia's invasion of change escala eady grappling with the mic. Floods in Australia sed thousands of deaths, and South Salam caused finanzands of dealth, hours loss (Edular) in 2022 (Indicators 11:26), with post of Jaharis in consumit, bases: Wallers caused and Jaharis in consumit, bases: Wallers caused and Tablys, and I error theory and the salar structures of the salar line margorithm, including Australia, and the UK Willia (Josens, Tairlys, Palan, and the UK William and the salar structures in the salar structures of the salar structures and the salar structure of the salar structure and the s r than 65 years, and age) were exposed ays in 2021 than ren 2000-04 and anging climate is affecting the of emerging diseases and co-epidemics

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01540-9/fulltext



heat-related deaths increase between 2000-04 and 2017-21

470b potential labor hours lost due to heat exposure globally in 2021

more people reporting food annually in 1981-2010

s253b damage worth in 2021 caused by extreme weather events



insecurity in 2020 than

months suitable for malaria ~31% increased Americas, 13.8% in Africa

12%

likelihood increase of dengue transmission from 1951-60 to 2012-21



Climate policy developments over time

1992 UN Framework Convention on Climate Change is established				2015 Science Based Targets initiative (SBTi) and Task force on Climate Related Financial Disclosures (TCFD) are established			Financial	
	1972 UN Environment Program (UNEP) is formed		1995 First Conference of the Parties (COP1)	1997 Kyoto Protoc adopted (Co		2015 Paris Agreement (COP21)		2022 COP27 (Egypt)
1988 Intergovernmental Panel on Climate Change (IPCC) is established				2014 IPCC's Fifth Assessment Report (AR5)		2018 IPCC's Special Report on Global Warming		
	IP	990 CC's First eport (A	it Assessment .R1)					

85 © 2022 Moderna, Inc. All rights reserved.


We follow the Greenhouse Gas Protocol Standards for development of our emissions inventory

GHG from human activities (e.g., CO_2 , CH_4 , N_20 , HCFs, etc.) are accounted for in three "scopes"

Scope 1 Direct emissions from owned or controlled sources (e.g., fossil fuels usage)

Scope 2 Indirect emissions from the generation of purchased energy (e.g., purchased electricity)

Scope 3 Indirect emissions that occur in the value chain (not included in Scopes 1 & 2)



Greenhouse Gas (GHG) Protocol







moderna

We understand the urgency to limit global warming to 1.5°C



Moderna is committed to achieve **net-zero** carbon emissions in our global operations (Scopes 1 & 2) by 2030

For Scope 3, Moderna is committed to defining a near-term science-based target and evaluating a long-term target





We are joining companies taking action to halve carbon emissions



The Science Based Targets initiative (SBTi) drives ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.

In partnership with:






INSTITUTE



How it works:



moderno

https://sciencebasedtargets.org/

As we scale our company, we are committed to protecting the planet



Current focus areas:


- LEED design in new sites and buildings
- Net-zero carbon emissions in global operations (Scopes 1 & 2) by 2030
- Partner with suppliers to reduce Scope 3 carbon emissions

Building a new HQ and R&D operations low-carbon building in Cambridge




moderna

Taking first steps in our journey




Established 2021 base year emissions for Scopes 1 & 2 (3rd party data assurance pending)



2021 CO2e Emissions (metric tons)

Committed to define science-based carbon reduction targets

Similar to peers in pharma and biotech, Scope 3 accounts for more than 90% of our carbon emissions





Already taking steps to understand the carbon footprint of our value chain





Established 2021 GHG Scope 3 Baseline, pending third party verification



Committed to define near-term science-based target and evaluate long-term Scope 3 target



100% subsidized green transportation across our campuses in the U.S.



Piloting biofuel and Sustainable Aviation Fuel to reduce CO2 emissions in transportation and distribution



Already seeking solutions to decarbonize value chain

HVO Pilot with Kuehne+Nagel

3,700 KM (2,300 mi) round trip

One fuel-up with HVO



Mission to reduce CO2 by 90%

What is Hydrotreated Vegetable Oil (HVO) fuel?

High quality **diesel fuel** made from renewable, sustainable raw materials, e.g., food waste. It is biodegradable and non-toxic.





We will continue our journey and focus on key milestones

Complete climate risk scenario analysis


Submit science-based targets for official validation by SBTi



SCIENCE BASED TARGETS

Intention to report to CDP and align with TCFD recommendations





Governance & Ethics

Shannon Thyme Klinger

Chief Legal Officer & Corporate Secretary



Board of Directors – Current Composition



Noubar Afeyan, PhD

Co-founder and Chairman, Moderna; CEO, Flagship Pioneering

Committees: Nom Gov (Chair), Product



Sandra Horning, MD

Co-Founder and Advisor, EQRx; Former Chief Medical Officer of Genentech/Roche

Committees: Product (Chair)

Elizabeth (Betsy) Nabel, M.D.

Executive Vice President for Strategy at ModeX Therapeutics; former President of Brigham Health

Committees: Nom Gov, Product



Stéphane Bancel

Chief Executive Officer, Moderna; Former CEO at bioMérieux, managing director at Eli Lilly



Robert Langer, ScD

Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT

Committees: Nom Gov



Stephen Berenson

Managing Partner, Flagship Pioneering; Former Vice Chairman of JP Morgan Investment Bank

Committees: Audit, Comp (Chair)



François Nader, MD

Former President, CEO and Executive Director, NPS Pharmaceuticals

Committees: Comp, Product



Paul Sagan

Senior Advisor and Executive in Residence, General Catalyst; Former CEO, Akamai

Committees: Audit, Nom Gov



Elizabeth Tallett


Former Principal, Hunter Partners; Former President and CEO, Transcell Technologies

Committees: Audit (Chair), Comp



2022 Board Highlights

From 2021 Proxy Statement





ESG oversight starts with the Board and Committees

Board Committees ESG oversight:

Audit Committee	Compensation and Talent Committee	Nominating and Corporate Governance Committee	Product Development Committee	
 Risk Assessment & Management 	 Human Capital Management 	 ESG strategy and metrics Climate-related risks and opportunities 	• Clinical trial design, incl. diversity	
 Internal audit and compliance functions 	 Belonging, Inclusion and Diversity strategy 	 Political engagement and disclosure 	 Product quality & safety 	
 Cybersecurity 		 Moderna Charitable Foundation 		

Recent Board	Access initiatives, Moderna's patent pledge, facilitation of dose donations from countries with
oversight of	excess supply
	 Net-zero carbon emissions commitment (Scopes 1 & 2) by 2030
ESG initiatives	 Moderna Charitable Foundation, initial endowment of \$50 million

moderna

99

Moderna continues to embed accountability for ESG throughout the organization

ESG accountability at Executive Committee level:



- Overseeing additional elements of ESG initiatives
- Shannon Klinger, Chief Legal Officer leads Moderna's ESG strategy
- Juan Andres / Jerh Collins, Chief Technical Operations & Quality Officer leads carbon reduction efforts
- Arpa Garay, Chief Commercial Officer oversees access initiatives
- Tracey Franklin, Chief Human Resources Officer oversee human capital initiatives
- Stephen Hoge, President oversees clinical trials, including diversity efforts in clinical trials

Annual bonus program builds in ESG metrics



- Human capital ESG metrics in 2021 & 2022, focused on belonging and engagement
- Vaccine availability in low- and middle-income countries metric in 2022

ESG is embedded in our Corporate strategic objectives


"Act responsibly toward our patients, employees and communities" objective in 2022



Evolving our Compliance policies, aligned with our values

Moderna's **Code of Ethics & Business Conduct** is our guide for ethical decision making – doing the right thing, the right way, every day!

Effective **January 1**, **2023**, Moderna's reimagined, principles-based Code of Ethics & Business Conduct:



#LivingOurCode campaign was launched October 2022, to familiarize employees with our reimagined Code



Building a supply chain that reflects our values

Starting our journey by increasing transparency across our supply chain

• Implemented Third Party Code of Business Conduct* outlining our expectations of suppliers

2022-2023 Building Program Foundations


- Launching Sustainable & Responsible Procurement program & assessment of key suppliers
- Adding contractual clauses in key supplier agreements
- Speak Up Hotline available for individuals to voice concerns or questions
- Published UK Modern Slavery Act Statement 2021




moderno

Committment to transparency since the beginning of our journey

Key highlights 2021 / 2022






Concluding Remarks

Stéphane Bancel

Chief Executive Officer



We believe our ESG journey will help Moderna become one of the most impactful companies



With the potential of **our science** comes a **responsibility to the multitude of patients** our technology could help

We have a responsibility to our employees to provide fulfilling, purposeful careers, and that our employees are rewarded for their dedication

We can and should **use our expertise and resources** to **give back to the communities** in which we operate

We have a responsibility to do our part to **ensure the sustainability of our planet**, and we will consider our impact on the environment in the decisions that we make

We must hold ourselves to **high ethical standards across all areas of our business** and with our stakeholders—both internal and external—while **ensuring we have the governance and practices** in place to meet these standards

Thank you

Collaborators, investigators, patients and their families, employees and investors...!

mmm

